- Oops!Something went wrong.Please try again later.
new genvirotm technology anticipated to be commercial ready in summer 2020, government fast track and waivers begun, cost per screen expected to be $4.95, unique reporting method to be used
LOS ANGELES, CA / ACCESSWIRE / March 3, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate Precis products manufactured for International markets.
Today, in a break-through discussed for the first time, DECN announces in this first of three releases, expected in the next 10 days, the introduction of our new screening methodology for the Coronavirus (Covid19). Our product is timely, simple to use, cost effective and will be commercial ready in the summer of 2020.
Keith Berman, CEO of DECN commented, "We have the technology perfected which will take months off of the development schedule. Our impedance powered diagnostic will be field tested at ground-zero in Daegu, Korea, where 700+ people have already been overcome by Coronavirus (COVID19) and where all of the clinical studies for our "Gen" products were tested. Our timing here is spot-on."
DECN also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. The company has also just introduced its GenExpidient! Universal Translator for bio-sensor devices of different manufacture. And finally the company is rolling out its GenUltimate TBG ("Dragonfly") product in International markets. The TBG Precise meter is now complete and available for US license to our strategic partner.
Mr. Berman concluded, "I want to say straight on that we have developed a Coronavirus screening method, not a cure or a vaccine for this virus. That being said, our screening method should allow for 80% of the suspected carriers of Coronavirus to exit the quarantine systems in the places where Coronavirus is rampant. But we are not done with our GenViro development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS. The cost of our test kits will be sold in a price range of $4.95 to $7.95 per use. We plan to provide our diagnostics initially for use at hospitals, doctors' offices, and clinics. Once production ramps up, we will offer testing kits and meters to patients for testing at-home.
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company's GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico but is for sale in select International markets since late February 2020.
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of March 2, 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
SOURCE: Decision Diagnostics Corp.
View source version on accesswire.com: